Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Bisantrene for R/R AML patients

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses the results of a Phase II study (NCT03820908) assessing the clinical efficacy of bisantrene, an anthracene with anthracycline-like activity, in a cohort of heavily pre-treated patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). Earlier studies have shown bisantrene to be an effective salvage therapy in R/R AML, without causing notable cardiotoxicity, a concern with anthracycline use. The study found that bisantrene induced clinical responses in 4 out of 10 patients in the study and had acceptable toxicity. Further investigations will assess bisantrene in combination with complementary anti-leukemic therapies. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.